SAM
ZVRA icon

Strategic Asset Management’s Zevra Therapeutics ZVRA Stock Holding History

Strategic Asset Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$260K Buy
41,743
+1,656
+4% +$9.38K 0.45% 41
2022
Q2 		$179K Hold
40,087
– – 0.29% 61
2022
Q1 		$202K Buy
40,087
+5,739
+17% +$36.5K 0.29% 60
2021
Q4 		$299K Sell
34,348
-17
-0% -$152 0.42% 43
2021
Q3 		$304K Buy
+34,365
New +$346K 0.43% 43

Other funds holding ZVRA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $246M AUM 27.83% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAM
Mystic Asset Management Warwick, Rhode Island $431M AUM 25.35% 1-Year Est. Return

Strategic Asset Management's ZVRA Position: Q3 2022 in Review

Strategic Asset Management increased its Zevra Therapeutics (ZVRA) stake by 4.1% in Q3 2022, buying an estimated $9.38K and bringing the position to 41,743 shares worth $260K. The position accounts for 0.45% of the portfolio, ranked #41.

Strategic Asset Management first reported a position in ZVRA in Q3 2021 and has held it in 5 quarters since. The position peaked at $304K in Q3 2021. 69 funds tracked by Wall St. Rank hold ZVRA as of Q3 2022.

  • Strategic Asset Management held 41,743 shares of Zevra Therapeutics worth $260K as of Q3 2022.
  • Strategic Asset Management bought 1,656 Zevra Therapeutics shares in Q3 2022, an estimated $9.38K.
  • Zevra Therapeutics made up 0.45% of Strategic Asset Management's portfolio in Q3 2022, its #41 holding.
  • Strategic Asset Management first reported a position in Zevra Therapeutics in Q3 2021 and has held it in 5 quarters since.
  • Strategic Asset Management's Zevra Therapeutics position peaked at $304K in Q3 2021.
  • 69 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2022.

Based on Strategic Asset Management's 13F filing for Q3 2022, filed 1 Nov 2022.